Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Philadelphia Chromosome 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1

Interventions

Specimen Handling 5Carboplatin 4X-Rays 3Rituximab 3Prednisone 3Nivolumab 3Magnetic Resonance Spectroscopy 3Abiraterone Acetate 3trastuzumab deruxtecan 2talquetamab 2pertuzumab 2pembrolizumab 2olaparib 2niraparib 2erdafitinib 2durvalumab 2belzutifan 2apalutamide 2acalabrutinib 2Trastuzumab 2Sunitinib 2Phantoms, Imaging 2Paclitaxel 2Immunoglobulin G 2Disulfides 2Dexamethasone 2Dasatinib 2Cyclophosphamide 2Crizotinib 2CT-P10 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has announcements × asciminib × 30 days × Clear all
NCT04971226 2026-06-05

A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP

Novartis

Phase 3 Active not recruiting
405 enrolled 18 charts 1 FDA
MyeloidOther hematologic neoplasm

Philadelphia Chromosome, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡